Bonnie Schlitt
Family · Vero Beach, FLNPI 1649558594
Payments from drug & device makers
Across 138 payments — averaging $24.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$431
- Bayer$378
- GSK$364
- Astellas Pharma US Inc$322
- Merck$235
- Gilead$211
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,37498%
- Education$662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $431 |
| Bayer | 9 | $378 |
| GSK | 15 | $364 |
| Astellas Pharma US Inc | 10 | $322 |
| Merck | 10 | $235 |
| Gilead | 9 | $211 |
| Novo Nordisk | 4 | $162 |
| Mayne Pharma Commercial LLC | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $111 |
| Corcept Therapeutics | 5 | $102 |
| Medtronic | 1 | $101 |
| Pfizer | 6 | $97 |
| Viiv Healthcare Company | 4 | $94 |
| Teva Pharmaceuticals USA, Inc. | 4 | $82 |
| Hologic Sales And Service, LLC | 3 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $57 |
| Cranial Technologies, Inc | 3 | $51 |
| Boston Scientific | 2 | $50 |
| Neurocrine Biosciences, Inc. | 3 | $47 |
| Lilly USA, LLC | 3 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Exact Sciences | 2 | $40 |
| Amgen | 2 | $36 |
| Insmed, Inc. | 1 | $33 |
| Alkermes, Inc. | 1 | $24 |
| Fresenius Kabi USA, LLC | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| AstraZeneca | 1 | $16 |
| Organon | 1 | $16 |
| Novartis | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Qiagen, LLC | 1 | $13 |
| Abbott | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$250
- Veozah$125
- ANNOVERA$125
- VOQUEZNA$111
- ClosureFast$101
How this compares
$3,440 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 107 | $127,869 |
| OzempicSemaglutide | 105 | $121,798 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 23 | $94,825 |
| JardianceEmpagliflozin | 29 | $38,642 |
| EliquisApixaban | 44 | $29,010 |
| FarxigaDapagliflozin Propanediol | 15 | $13,670 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $13,542 |
| RybelsusSemaglutide | 11 | $12,662 |
| QuliptaAtogepant | 11 | $11,831 |
| Repatha SureclickEvolocumab | 11 | $9,498 |
| LivaloPitavastatin Calcium | 20 | $9,387 |
| Victoza 3-PakLiraglutide | 12 | $9,386 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 20 | $3,956 |
| EdarbiAzilsartan Medoxomil | 13 | $3,552 |
| Dexlansoprazole DrDexlansoprazole | 19 | $2,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $162 | $134,460116 claims |
| Lilly USA, LLCMounjaro | $44 | $127,869107 claims |
| GileadGenvoya | $211 | $94,82523 claims |
| PfizerEliquis | $97 | $29,01044 claims |
| GSKTrelegy Ellipta, Shingrix | $364 | $17,49835 claims |
| AstraZenecaFarxiga | $16 | $13,67015 claims |
| AbbVieQulipta, Synthroid | $431 | $13,27034 claims |
| Sanofi-aventis U.S. LLCLantus | $44 | $70911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Vero Beach
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.